These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 21798108)
1. Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD. Buitelaar JK; Trott GE; Hofecker M; Waechter S; Berwaerts J; Dejonkheere J; Schäuble B Int J Neuropsychopharmacol; 2012 Feb; 15(1):1-13. PubMed ID: 21798108 [TBL] [Abstract][Full Text] [Related]
2. Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate. Buitelaar JK; Casas M; Philipsen A; Kooij JJ; Ramos-Quiroga JA; Dejonckheere J; van Oene JC; Schäuble B Psychol Med; 2012 Jan; 42(1):195-204. PubMed ID: 21733214 [TBL] [Abstract][Full Text] [Related]
3. Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate. Rösler M; Ginsberg Y; Arngrim T; Adamou M; Niemelä A; Dejonkheere J; van Oene J; Schäuble B World J Biol Psychiatry; 2013 May; 14(4):282-90. PubMed ID: 21517701 [TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan. Takahashi N; Koh T; Tominaga Y; Saito Y; Kashimoto Y; Matsumura T World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065 [TBL] [Abstract][Full Text] [Related]
5. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder. Fallu A; Richard C; Prinzo R; Binder C Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study. Casas M; Rösler M; Sandra Kooij JJ; Ginsberg Y; Ramos-Quiroga JA; Heger S; Berwaerts J; Dejonckheere J; van der Vorst E; Schäuble B World J Biol Psychiatry; 2013 May; 14(4):268-81. PubMed ID: 22106853 [TBL] [Abstract][Full Text] [Related]
7. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents. Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529 [TBL] [Abstract][Full Text] [Related]
8. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate. Buitelaar JK; Sobanski E; Stieglitz RD; Dejonckheere J; Waechter S; Schäuble B J Clin Psychiatry; 2012 Aug; 73(8):1097-102. PubMed ID: 22780962 [TBL] [Abstract][Full Text] [Related]
9. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198 [TBL] [Abstract][Full Text] [Related]
10. Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial. Kooij JJ; Rösler M; Philipsen A; Wächter S; Dejonckheere J; van der Kolk A; van Agthoven M; Schäuble B BMC Psychiatry; 2013 Jan; 13():36. PubMed ID: 23347693 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study. Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989 [TBL] [Abstract][Full Text] [Related]
12. Long-term (1 year) safety and efficacy of methylphenidate modified-release long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity disorder: a 26-week, flexible-dose, open-label extension to a 40-week, double-blind, randomised, placebo-controlled core study. Ginsberg Y; Arngrim T; Philipsen A; Gandhi P; Chen CW; Kumar V; Huss M CNS Drugs; 2014 Oct; 28(10):951-62. PubMed ID: 25183661 [TBL] [Abstract][Full Text] [Related]
13. Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate. Retz W; Rösler M; Ose C; Scherag A; Alm B; Philipsen A; Fischer R; Ammer R; World J Biol Psychiatry; 2012 Jan; 13(1):48-59. PubMed ID: 21155632 [TBL] [Abstract][Full Text] [Related]
14. Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate. Buitelaar JK; Kooij JJ; Ramos-Quiroga JA; Dejonckheere J; Casas M; van Oene JC; Schäuble B; Trott GE Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):554-60. PubMed ID: 21185347 [TBL] [Abstract][Full Text] [Related]
15. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study. Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533 [TBL] [Abstract][Full Text] [Related]
16. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study. Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126 [TBL] [Abstract][Full Text] [Related]
17. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up. Su Y; Yang L; Stein MA; Cao Q; Wang Y J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845 [TBL] [Abstract][Full Text] [Related]
18. Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder. Childress AC; Kollins SH; Foehl HC; Newcorn JH; Mattingly G; Kupper RJ; Adjei AL J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):58-68. PubMed ID: 32125903 [No Abstract] [Full Text] [Related]
19. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. Riggs PD; Winhusen T; Davies RD; Leimberger JD; Mikulich-Gilbertson S; Klein C; Macdonald M; Lohman M; Bailey GL; Haynes L; Jaffee WB; Haminton N; Hodgkins C; Whitmore E; Trello-Rishel K; Tamm L; Acosta MC; Royer-Malvestuto C; Subramaniam G; Fishman M; Holmes BW; Kaye ME; Vargo MA; Woody GE; Nunes EV; Liu D J Am Acad Child Adolesc Psychiatry; 2011 Sep; 50(9):903-14. PubMed ID: 21871372 [TBL] [Abstract][Full Text] [Related]
20. Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder. Zheng Y; Wang YF; Qin J; Wang LW; Zou LP; Jin XM; Xu T; Wang Y; Qi YL; Gong ME; Yin QY; Mai JN; Jing J; Luo XY; Ma HW; Li HB; Xie L; Li Y; Kuang GF; Yi MJ; Wang F; Zhu XH; Yao YB Chin Med J (Engl); 2011 Oct; 124(20):3269-74. PubMed ID: 22088519 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]